This study was performed to develop a liquid crystalline system (LCS) incorporated with terpinen-4-ol and nystatin to evaluate its antifungal, antibiofilm, and synergistic/modulatory activity against Candida albicans. The LCS was composed of a dispersion containing 40% propoxylated and ethoxylated cetyl alcohol, 40% oleic acid, and 0.5% chitosan dispersion. According to analysis by polarized light microscopy, rheology, and mucoadhesion studies, the incorporation of 100% artificial saliva increased the pseudoplasticity, consistency index, viscosity, and mucoadhesion of the formulation. The minimum inhibitory concentration, minimum fungicidal concentration, and rate of biofilm development were used to evaluate antifungal activity; the LCS containing terpinen-4-ol and nystatin effectively inhibited C. albicans growth at a lower concentration, displaying a synergistic action. Therefore, LCS incorporated with terpinen-4-ol and nystatin is a promising alternative for preventing and treating infections and shows potential for the development of therapeutic strategies against candidiasis. Candida species are pathogenic yeasts and the leading causes of several major fungal infections in humans. These infections can be caused by increased use of immunosuppressive therapies, acquired immunodeficiency syndrome, and the emergence of drug resistance 1,2. Candida albicans is the most commonly isolated yeast species in the oral microbiota and may cause infections in the presence of other associated factors such as vertical dimension reduction, unstable occlusion, old prostheses, and roughness causing local or systemic infection 3. Among the different virulence factors, the initial adhesion resulting in biofilm formation on abiotic and biotic surfaces plays a critical role in the pathogenesis of C. albicans. Several antifungal agents are used to prevent and treat oral candidiasis, such as polyenes, ketoconazole, and miconazole 4. However, the clinical presentation of less susceptible strains leads to treatment failure, increasing disease recurrence. Several mechanisms of azole-resistant species have been reported, including those with changes in the cell wall or plasma membrane to impair azole uptake; overexpression or mutations in the target enzyme of azoles; and efflux of drugs mediated by membrane transport proteins 5. Resistance appears to increase proportionally with the extent of previous exposure to antifungal drugs. In addition, studies have shown some medications may cause injuries in the kidney and liver 6 , highlighting the need to develop new therapeutic strategies and search for agents with novel mechanisms of action that may be used independently or in combination with conventional medicines. Drug resistance is a matter of concern. The search for new agents may lead to the development of new antifungal agents that are effective against biofilms. Although the polyene nystatin is widely used to control and reduce oral fungal infections, polyenes are highly toxic to the host and their prolonged use can lead to drug res...